Patents by Inventor Yen-Ming Hsu
Yen-Ming Hsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11996467Abstract: A semiconductor device includes first and second semiconductor fins extending from a substrate and a source/drain region epitaxially grown in recesses of the first and second semiconductor fins. A top surface of the source/drain region is higher than a surface level with top surfaces of the first and second semiconductor fins. The source/drain region includes a plurality of buffer layers. Respective layers of the plurality of buffer layers are embedded between respective layers of the source/drain region.Type: GrantFiled: May 15, 2023Date of Patent: May 28, 2024Assignee: TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD.Inventors: Tzu-Hsiang Hsu, Ting-Yeh Chen, Wei-Yang Lee, Feng-Cheng Yang, Yen-Ming Chen
-
Patent number: 11955519Abstract: A semiconductor device includes an epitaxial substrate. The epitaxial substrate includes a substrate. A strain relaxed layer covers and contacts the substrate. A III-V compound stacked layer covers and contacts the strain relaxed layer. The III-V compound stacked layer is a multilayer epitaxial structure formed by aluminum nitride, aluminum gallium nitride or a combination of aluminum nitride and aluminum gallium nitride.Type: GrantFiled: April 17, 2023Date of Patent: April 9, 2024Assignee: UNITED MICROELECTRONICS CORP.Inventors: Yu-Ming Hsu, Yu-Chi Wang, Yen-Hsing Chen, Tsung-Mu Yang, Yu-Ren Wang
-
Recombinant intravenous immunoglobulin (RIVIG) compositions and methods for their production and use
Patent number: 11801286Abstract: Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purification and use of rIVIG proteins. The compositions comprise oligomeric Fc molecules which bind to Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules for the treatment of immune disorders including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves Disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins can also be used as immunomodulators in patients to reduce the immune rejection of organ transplants, stem cell transplants and bone marrow transplantation.Type: GrantFiled: March 29, 2022Date of Patent: October 31, 2023Assignee: AB Biosciences, Inc.Inventors: Yen-Ming Hsu, Jeng-Shin Lee, Hsiu-Ching Chang -
Patent number: 11769032Abstract: An embodiment of the present invention provides a counting information updating method for a portable electronic device having a plurality of spheres connected with each other. The method includes: generating an angular velocity signal by a first sensor of the portable electronic device and generating an acceleration signal by a second sensor of the portable electronic device in response to a sphere moving operation; and estimating counting information corresponding to the sphere moving operation by using the angular velocity signal with an assistance of the acceleration signal.Type: GrantFiled: December 24, 2020Date of Patent: September 26, 2023Assignee: Acer IncorporatedInventors: Chih-Chieh Chien, Yi-Chun Chung, Pei-Wen Jung, Yen-Ming Hsu
-
Patent number: 11647817Abstract: A wearable electronic device includes a plurality of secondary spheres and a main sphere connected in series. The main sphere includes a lower cover, an upper cover, a threading pillar, a chip, and a wireless transmitting component. The lower cover has a first assembling space. The upper cover is disposed on the lower cover and covers the first assembling space. The upper cover has a second assembling space communicated with the first assembling space. The threading pillar is clamped between the lower cover and the upper cover and is located in the first assembling space and the second assembling space. Both of the chip and the wireless transmitting component are disposed in the first assembling space, and the wireless transmitting component is electrically connected to the chip. An assembling method of a wearable electronic device is also provided.Type: GrantFiled: November 14, 2019Date of Patent: May 16, 2023Assignee: Acer Gadget Inc.Inventors: Yen-Ming Hsu, Pei-Wen Jung
-
Publication number: 20230135399Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD4OL) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.Type: ApplicationFiled: September 7, 2022Publication date: May 4, 2023Inventors: LINDA C. BURKLY, JANINE L. FERRANT-ORGETTAS, ELLEN A. GARBER, YEN-MING HSU, LIHE SU, FREDERICK R. TAYLOR, RALPH ADAMS, DEREK THOMAS BROWN, ANDREW GEORGE POPPLEWELL, MARTYN KIM ROBINSON, ANTHONY SHOCK, KERRY LOUISE TYSON
-
RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND USE
Publication number: 20220233658Abstract: Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purification and use of rIVIG proteins. The compositions comprise oligomeric Fc molecules which bind to Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules for the treatment of immune disorders including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves Disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins can also be used as immunomodulators in patients to reduce the immune rejection of organ transplants, stem cell transplants and bone marrow transplantation.Type: ApplicationFiled: March 29, 2022Publication date: July 28, 2022Inventors: Yen-Ming Hsu, Jeng-Shin Lee, Hsiu-Ching Chang -
Publication number: 20220213208Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: ApplicationFiled: July 30, 2021Publication date: July 7, 2022Applicant: Biogen MA Inc.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use
Patent number: 11304994Abstract: Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purification and use of rIVIG proteins. The compositions comprise oligomeric Fc molecules which bind to Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules for the treatment of immune disorders including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves Disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins can also be used as immunomodulators in patients to reduce the immune rejection of organ transplants, stem cell transplants and bone marrow transplantation.Type: GrantFiled: March 29, 2017Date of Patent: April 19, 2022Assignee: AB Biosciences, Inc.Inventors: Yen-Ming Hsu, Jeng-Shin Lee, Hsiu-Ching Chang -
Patent number: 11111307Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: GrantFiled: July 3, 2018Date of Patent: September 7, 2021Assignee: Biogen MA Inc.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Publication number: 20210117753Abstract: An embodiment of the present invention provides a counting information updating method for a portable electronic device having a plurality of spheres connected with each other. The method includes: generating an angular velocity signal by a first sensor of the portable electronic device and generating an acceleration signal by a second sensor of the portable electronic device in response to a sphere moving operation; and estimating counting information corresponding to the sphere moving operation by using the angular velocity signal with an assistance of the acceleration signal.Type: ApplicationFiled: December 24, 2020Publication date: April 22, 2021Applicant: Acer IncorporatedInventors: Chih-Chieh Chien, Yi-Chun Chung, Pei-Wen Jung, Yen-Ming Hsu
-
Patent number: 10915807Abstract: An embodiment of the present invention provides a counting information updating method for a portable electronic device having a plurality of spheres connected with each other. The method includes: generating an angular velocity signal by a first sensor of the portable electronic device and generating an acceleration signal by a second sensor of the portable electronic device in response to a sphere moving operation; and estimating counting information corresponding to the sphere moving operation by using the angular velocity signal with an assistance of the acceleration signal.Type: GrantFiled: August 28, 2019Date of Patent: February 9, 2021Assignee: Acer IncorporatedInventors: Chih-Chieh Chien, Yi-Chun Chung, Pei-Wen Jung, Yen-Ming Hsu
-
Publication number: 20210022461Abstract: A wearable electronic device includes a plurality of secondary spheres and a main sphere connected in series. The main sphere includes a lower cover, an upper cover, a threading pillar, a chip, and a wireless transmitting component. The lower cover has a first assembling space. The upper cover is disposed on the lower cover and covers the first assembling space. The upper cover has a second assembling space communicated with the first assembling space. The threading pillar is clamped between the lower cover and the upper cover and is located in the first assembling space and the second assembling space. Both of the chip and the wireless transmitting component are disposed in the first assembling space, and the wireless transmitting component is electrically connected to the chip. An assembling method of a wearable electronic device is also provided.Type: ApplicationFiled: November 14, 2019Publication date: January 28, 2021Applicant: GadgeTek Inc.Inventors: Yen-Ming Hsu, Pei-Wen Jung
-
Publication number: 20200074265Abstract: An embodiment of the present invention provides a counting information updating method for a portable electronic device having a plurality of spheres connected with each other. The method includes: generating an angular velocity signal by a first sensor of the portable electronic device and generating an acceleration signal by a second sensor of the portable electronic device in response to a sphere moving operation; and estimating counting information corresponding to the sphere moving operation by using the angular velocity signal with an assistance of the acceleration signal.Type: ApplicationFiled: August 28, 2019Publication date: March 5, 2020Applicant: Acer IncorporatedInventors: Chih-Chieh Chien, Yi-Chun Chung, Pei-Wen Jung, Yen-Ming Hsu
-
Publication number: 20190233530Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.Type: ApplicationFiled: April 10, 2019Publication date: August 1, 2019Inventors: Linda C. Burkly, Janine L. Ferrant-Orgettas, Ellen A. Garber, Yen-Ming Hsu, Lihe Su, Frederick R. Taylor, Ralph Adams, Derek Thomas Brown, Andrew George Popplewell, Martyn Kim Robinson, Anthony Shock, Kerry Louise Tyson
-
Publication number: 20190161552Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: ApplicationFiled: July 3, 2018Publication date: May 30, 2019Applicant: Biogen MA Inc.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND USE
Publication number: 20190111115Abstract: Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purification and use of rIVIG proteins. The compositions comprise oligomeric Fc molecules which bind to Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules for the treatment of immune disorders including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves Disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins can also be used as immunomodulators in patients to reduce the immune rejection of organ transplants, stem cell transplants and bone marrow transplantation.Type: ApplicationFiled: March 29, 2017Publication date: April 18, 2019Inventors: Yen-Ming Hsu, Jeng-Shin Lee, Hsiu-Ching Chang -
Publication number: 20170129951Abstract: The present invention provides novel, rationally designed human control antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have well characterized variable domains that have been designed to minimize or eliminate antigen binding without altering gross antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.Type: ApplicationFiled: October 26, 2016Publication date: May 11, 2017Inventors: HSIU-CHING CHANG, YEN-MING HSU, JENG-SHIN LEE
-
Publication number: 20170029518Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: ApplicationFiled: March 9, 2016Publication date: February 2, 2017Applicant: Biogen MA Inc.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Patent number: 9494597Abstract: The present invention provides novel, rationally designed human control antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have well characterized variable domains that have been designed to minimize or eliminate antigen binding without altering gross antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.Type: GrantFiled: April 2, 2013Date of Patent: November 15, 2016Assignee: AB BIOSCIENCES, INC.Inventors: Hsiu-Ching Chang, Yen-Ming Hsu, Jeng-Shin Lee